Coronary Artery Bypass Graft News and Research RSS Feed - Coronary Artery Bypass Graft News and Research

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company. [More]
Racial disparities exist for black and Hispanic patients undergoing major surgeries in U.S. hospitals

Racial disparities exist for black and Hispanic patients undergoing major surgeries in U.S. hospitals

Considerable racial disparities exist in surgical outcomes for black and Hispanic patients undergoing major cancer and non-cancer surgeries in U.S. hospitals, even among institutions that have already enrolled in a national surgical quality improvement initiative. [More]
Older, low-income female patients less likely to complete cardiac rehabilitation after bypass surgery

Older, low-income female patients less likely to complete cardiac rehabilitation after bypass surgery

Bypass patients who are older, female and/or from lower-income neighbourhoods are more likely to face delays in beginning cardiac rehabilitation (CR), making them less likely to complete CR, which can lead to a higher mortality risk, suggests a new study. [More]
Multimodal non-invasive neurological monitoring reduces postoperative delirium in older cardiac patients

Multimodal non-invasive neurological monitoring reduces postoperative delirium in older cardiac patients

Patients undergoing cardiac surgery are at an increased risk of developing delirium and other changes in cognitive function in the days following surgery. However, new research presented at the ANESTHESIOLOGY 2015 annual meeting, found using monitors to track depth of anesthesia and oxygenation levels in older patients' brains during cardiac surgery significantly reduced their incidence of postoperative delirium and associated cognitive decline. [More]
Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States. [More]
Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada. [More]
Statins reduce risk of death by 67% in CABG surgery

Statins reduce risk of death by 67% in CABG surgery

Research presented at this year's Euroanaesthesia exploring the protective effect of various heart medications that patients are taking before undergoing coronary artery bypass graft (CABG) surgery concludes that statins reduce the risk of death by two thirds, or 67 percent, while no consistent effects were seen for other medications. [More]
Study finds botulinum toxin injections in epicardial fat pads reduce AF risk immediately following surgery and after one year of follow-up

Study finds botulinum toxin injections in epicardial fat pads reduce AF risk immediately following surgery and after one year of follow-up

AF is the most common arrhythmia complicating cardiac surgery and occurs in approximately 30-40 percent of patients undergoing CABG surgery... [More]
Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII. [More]
Egalet announces net revenues of $1.9 million for 2014

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014. [More]
FDA receives IDE application for CytoSorbents' CytoSorb cardiac surgery trial

FDA receives IDE application for CytoSorbents' CytoSorb cardiac surgery trial

CytoSorbents Corporation, a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced today that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to conduct its proposed clinical trial using CytoSorb® intra-operatively in patients undergoing complex cardiac surgery requiring the use of a heart-lung machine. [More]
FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject (diclofenac sodium) Injection, a proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic. [More]
Research: Reducing emergency surgery for common procedures could cut health care costs

Research: Reducing emergency surgery for common procedures could cut health care costs

New research indicates that reducing emergency surgery for three common procedures by 10 percent could cut $1 billion in health care costs over 10 years. [More]
Baylor Scott & White Health forms alliance with Cleveland Clinic

Baylor Scott & White Health forms alliance with Cleveland Clinic

Baylor Scott & White Health today announces an alliance with Cleveland Clinic's Sydell and Arnold Miller Family Heart & Vascular Institute. [More]
Study: Preoperative interventions improve outcomes of patients undergoing CABG surgery

Study: Preoperative interventions improve outcomes of patients undergoing CABG surgery

A quality improvement initiative improved the outcomes of patients undergoing cardiac surgery at select medical centers in northern New England, according to a study in the December issue of Critical Care Nurse (CCN). [More]
Preoperative IV ibuprofen improves quality of recovery after laparoscopic cholecystectomy surgery

Preoperative IV ibuprofen improves quality of recovery after laparoscopic cholecystectomy surgery

Cumberland Pharmaceuticals Inc. today announced that preoperative intravenous ibuprofen improved overall quality of recovery in patients undergoing laparoscopic cholecystectomy surgery. These results will be presented at the American Anesthesiology 2014 Annual Meeting in New Orleans, Louisiana. [More]
Surgical patient safety program significantly reduces cardiac surgical site infections

Surgical patient safety program significantly reduces cardiac surgical site infections

A common postoperative complication after open heart operations-infection at the surgical site-has been reduced by 77 percent at a Canadian hospital through its participation in the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP-), according to a new case study presented at the 2014 ACS NSQIP National Conference. [More]
Cumberland launches new Vaprisol product

Cumberland launches new Vaprisol product

Cumberland Pharmaceuticals Inc. today announced the launch of its active promotional campaign to support its new Vaprisol® product. [More]
Study: Repeat sternotomy for surgical aortic valve replacement safe for octogenarian patients

Study: Repeat sternotomy for surgical aortic valve replacement safe for octogenarian patients

Surgical aortic valve replacement generally improves patients' symptoms and prolongs survival. However, the perceived risk of surgical aortic valve replacement in patients over 80 may result in surgery being denied or a recommendation for alternative therapy. Investigators at the Mayo Clinic challenge the way these patients have been managed. [More]
FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults. [More]
Advertisement
Advertisement